Protagonist Therapeutics Inc (PTGX) — Capital Reinvestment Ratio
Latest as of March 2025:
0.00x
Protagonist Therapeutics Inc (PTGX) has a Capital Reinvestment Ratio of 0.00x as of March 2025, meaning it reinvests 0% of its operating cash flow ($125.36 Million) in capital expenditures ($545.00K). See PTGX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$125.36 Million
USD
Capital Expenditures
$545.00K
USD
Data as of
Mar 2025
Most recent filing
Protagonist Therapeutics Inc Capital Reinvestment Ratio (2017–2024)
This chart tracks Protagonist Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Protagonist Therapeutics Inc (2017–2024)
Year-by-year Capital Reinvestment Ratio for Protagonist Therapeutics Inc from 2017 to 2024. For live market cap and broader valuation context, see Protagonist Therapeutics Inc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.01x | $184.15 Million | $1.35 Million | ▼ -95.7% |
| 2017 | 0.17x | $3.87 Million | $666.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow